Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5552W HIGH $6.44
Volume
522.20 K
Value Traded
15.96 M
Short % Float
28.17%
-4.57%Week
-22.09%1 Month
-14.43%3 Month
-19.44%6 Month
-79.94%5 Year
-99.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
507.69 M
EPS (TTM)
-0.47
P/E Ratio
-
Ent. Value
21.96 M
Total Shares
194.39 M
Float Shares
183.68 M
Insiders
5.57%
Institutions
72.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALT Catalyst Timeline
Dated clinical, regulatory and corporate events for Altimmune, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Altimmune, Inc.
455Total events
7Upcoming
138Tier-1 (high impact)
2012 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutPemvidutideClinical Data
Reported positive topline data from RECLAIM Phase 2 trial in AUD
AUDsource ↗
▲Enrollment CompletePemvidutideTrial
Completed patient enrollment in RESTORE Phase 2 trial in ALD
ALDsource ↗
▲Topline ReadoutPemvidutideClinical Data
Positive topline results from RECLAIM Phase 2 trial
alcohol use disordersource ↗
●Oral PresentationPemvidutidePresentation
Conference call to discuss RECLAIM topline data
Alcohol Use Disordersource ↗
▲Primary Endpoint MetPemvidutideClinical Data
Primary endpoint met: reduction in heavy drinking days
alcohol use disordersource ↗
◆Trial InitiationPemvidutideTrial
PERFORMA Phase 3 trial initiation planned
metabolic dysfunction-associated steatohepatitissource ↗
●Quarterly UpdateCorporate
Reported $519 million in cash, cash equivalents and investments as of June 30, 2026
▲Poster PresentationPemvidutidePresentation
Poster presentation of new IMPACT Phase 2b data at EASL 2026
MASHsource ↗
▲AbstractPemvidutidePresentation
Abstract on 48-week results selected as 'Best of EASL 2026'
MASHsource ↗
▲Breakthrough Therapy DesignationPemvidutideDesignation
FDA granted Breakthrough Therapy Designation for pemvidutide in MASH
MASHsource ↗
▼Equity OfferingCorporate
Pricing of $225 million oversubscribed public offering of common stock and warrants
▼Equity OfferingCorporate
Completed oversubscribed public offering for $225.0 million gross proceeds
●Quarterly UpdateCorporate
Q1 2026 financial results: net loss $22.6 million, cash $332 million as of March 31, 2026
▲Breakthrough Therapy DesignationPemvidutideDesignation
FDA granted Breakthrough Therapy Designation for pemvidutide in MASH
MASHsource ↗
▲End Of Phase 2 MeetingPemvidutideFDA Meeting
Successful End-of-Phase 2 Meeting with FDA for MASH program
MASHsource ↗
▲Breakthrough Therapy DesignationPemvidutideDesignation
FDA granted Breakthrough Therapy Designation for pemvidutide in MASH
MASHsource ↗
▼Equity OfferingCorporate
Completed registered direct offering with Alyeska Investment Group for $75.0 million gross proceeds
▲Topline ReadoutPemvidutideClinical Data
Positive topline 48-week data from IMPACT Phase 2b trial of pemvidutide in MASH
MASHsource ↗
▲End Of Phase 2 MeetingPemvidutideFDA Meeting
Productive End-of-Phase 2 meeting with FDA; alignment on Phase 3 trial parameters
MASHsource ↗
●Oral PresentationPemvidutidePresentation
Conference call to review IMPACT Phase 2b 48-week data
MASHsource ↗
▲Full ResultsPemvidutideClinical Data
48-week data from IMPACT Phase 2b trial announced
metabolic dysfunction-associated steatohepatitissource ↗
▲End Of Phase 2 MeetingPemvidutideFDA Meeting
End-of-phase 2 meeting with FDA completed, alignment on Phase 3 parameters
MASHsource ↗
▲PublicationPemvidutidePresentation
Publication of 24-week IMPACT Phase 2b data in The Lancet
MASHsource ↗
▲Oral PresentationPemvidutidePresentation
Late-breaking oral presentation at AASLD The Liver Meeting 2025
MASHsource ↗
◆Late-BreakerPemvidutidePresentation
Late-breaking poster presentation of AI-based analysis of liver fibrosis reduction at AASLD The Liver Meeting 2025
MASHsource ↗
◆Oral PresentationPemvidutidePresentation
Late-breaking oral presentation of 24-week efficacy and safety data from IMPACT trial at AASLD The Liver Meeting 2025
MASHsource ↗
◆Poster PresentationPemvidutidePresentation
Late-breaking poster presentation of AI-based analyses of liver fibrosis reduction from IMPACT trial at AASLD The Liver Meeting 2025
MASHsource ↗
▲Enrollment CompletePemvidutideTrial
Patient recruitment and randomization completed in RECLAIM trial ahead of expected timeline
alcohol use disorder (AUD)source ↗
◆Oral PresentationPresentation
Management to participate in two upcoming investor conferences with webcast
▲Enrollment CompletePemvidutideTrial
Early completion of enrollment in RECLAIM Phase 2 trial for alcohol use disorder
alcohol use disordersource ↗
◆End Of Phase 2 MeetingPemvidutideFDA Meeting
End of Phase 2 meeting with FDA expected in Q4 2025
MASHsource ↗
Past FDA Catalysts and PDUFA Decisions
How ALT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | pemvidutide | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$638M
Pipeline Value
Fair Value
Valuation Signal
7
Drugs Scored
1.2x
rNPV / MCap
Top 15%
Micro Cap(rank 100 of 658)
Percentile Rank
Altimmune, Inc. carries a moderate pipeline score (51/100), with $1.6B risk-adjusted pipeline value, led by ALT-801 in Obesity/Overweight (Phase 2), across $189B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT-801 Small moleculeCompletedNCT05295875 | Obesity/Overweight | Phase 2 | COMPLETED | 391 | Sep 28, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pemvidutide BreakthroughFast Track | alcohol use disorder | Phase 2 | 2026-07-28 | p=0.0014; p=0.0049; p=0.0066; p=0.0075; p<0.0001; 9.1% at 24 weeksRead More | Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use DisorderRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WEAVER GREGORY LOfficer (Chief Financial Officer) | Option | 14,475 54,306 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.9 % | 58.52 M | 19.25 M |
ALT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-09 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALT ranks across every disease it competes in
Competitive Position is a premium feature
See how ALT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALT News
ALT▼ -6.5%on this news
Altimmune to Participate in Stifel Cardiometabolic Forum
Altimmune, Inc. will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026. The company is focused on developing pemvidutide, a dual-action therapy for serious liver diseases. This event will allow Altimmune to showcase its advancements and engage with investors.
Read more →ALTAltimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. The company's management will engage in a fireside chat to discuss their lead candidate, pemvidutide, which targets serious liver diseases. A webcast of the event will be available on Altimmune's website.
Read more →ALTAltimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune announced its financial results for Q2 2026, highlighting significant progress in its clinical trials. The company initiated the global PERFORMA Phase 3 trial for MASH and reported positive topline data from the RECLAIM Phase 2 trial in AUD. Additionally, patient enrollment in the RESTORE Phase 2 trial for ALD has been completed, with a strong cash position of $519 million.
Read more →ALTAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune, Inc. will report its second quarter 2026 financial results on August 12, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. The call will be accessible via a live webcast and will include a replay available for three months.
Read more →ALT▲ +5.6%on this newsshared move
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Altimmune has commenced the PERFORMA Phase 3 trial to evaluate pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). This trial follows positive results from the IMPACT Phase 2b study and aims to assess the drug's efficacy and safety in patients with moderate to advanced fibrosis. The trial is expected to provide data by 2029, potentially paving the way for regulatory approval.
Read more →ALTAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Altimmune announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder (AUD). The trial achieved its primary endpoint with a significant reduction in heavy drinking days and met important secondary endpoints recognized by the FDA. The company plans to request an End-of-Phase 2 meeting with the FDA to discuss further development.
Read more →ALTPemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAI
Read more →ALTNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Altimmune, Inc. announced positive results from the IMPACT Phase 2b trial of pemvidutide, showing concurrent improvements in non-invasive tests for metabolic dysfunction-associated steatohepatitis (MASH) at 24 weeks. The findings were supported by AI-based digital pathology analyses, indicating significant antifibrotic effects. The company plans to initiate a Phase 3 trial later this year.
Read more →ALTAltimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor confere
Read more →ALTAltimmune Announces First Quarter 2026 Financial Results and Business Update
Altimmune, Inc. reported its financial results for Q1 2026, highlighting a strong cash position of $535 million. The company plans to initiate the PERFORMA Phase 3 trial for pemvidutide in the second half of 2026, following its Breakthrough Therapy Designation from the FDA. Despite a net loss of $22.6 million, Altimmune remains focused on advancing its clinical trials for serious liver diseases.
Read more →ALTAltimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune, Inc. announced that results from its IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2026. The presentation will include 48-week efficacy and safety data, selected as 'Best of EASL 2026'. Additionally, late-breaking posters will cover new findings on liver fibrosis regression and cardiovascular risk factors.
Read more →ALT▲ +6.5%on this news
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Altimmune, Inc. will report its first quarter 2026 financial results on May 13, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Altimmune is developing pemvidutide, a therapy aimed at treating serious liver diseases.
Read more →ALTAltimmune Announces First Quarter 2026 Financial Results and Business Update Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026
Altimmune, Inc. announced its financial results for Q1 2026, revealing a robust cash position of $535 million as of April 30, 2026. The company is set to initiate the PERFORMA Phase 3 trial for pemvidutide targeting metabolic dysfunction-associated steatohepatitis in the second half of 2026. CEO Jerry Durso highlighted ongoing advancements, including topline data from RECLAIM Phase 2 AUD trial and completion of enrollment in RESTORE Phase 2 ALD trial. The company continues to focus on delivering pemvidutide for patients with serious liver diseases.
Read more →ALTAltimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. has successfully closed a $225 million oversubscribed public offering to fund its upcoming Phase 3 trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The offering included shares and warrants, with significant participation from notable investors. The company plans to utilize the proceeds for trial execution and general corporate purposes, aiming to initiate the trial in the second half of 2026.
Read more →ALT▼ -16.7%on this newsshared move
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. has announced the pricing of its oversubscribed public offering, which includes 64.25 million shares of common stock and accompanying warrants, aiming to raise approximately $225 million. The offering is set to close on or about April 24, 2026, and the proceeds will primarily fund the upcoming Phase 3 trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The offering is subject to market conditions.
Read more →ALTAltimmune Announces Proposed Underwritten Public Offering of Securities
Altimmune, Inc. has announced a proposed underwritten public offering of its common stock and accompanying warrants. The proceeds from this offering will primarily fund its upcoming Phase 3 trial for metabolic dysfunction-associated steatohepatitis (MASH). The offering is subject to market conditions, and there is no guarantee of completion or specific terms.
Read more →ALT▼ -17.9%on this news
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Altimmune, Inc. reported strong financial results for Q4 and full-year 2025, highlighting a robust cash position of $274 million. The company announced the upcoming initiation of a Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) and received FDA Breakthrough Therapy Designation. Positive data from ongoing trials in alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) further emphasize the potential of pemvidutide.
Read more →ALTAltimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Altimmune, a biopharmaceutical company, will report its fourth quarter and full year 2025 financial results on March 5, 2026. The management will host a conference call to discuss these results and provide a business update. The call will be accessible via webcast, and a replay will be available for three months.
Read more →ALT▲ +9.8%on this news
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Altimmune, Inc. has successfully closed a $75 million registered direct offering of 17,045,454 shares of common stock. The proceeds will support the upcoming Phase 3 trial for pemvidutide, a therapy for metabolic dysfunction-associated steatohepatitis (MASH). This offering enhances the company's financial stability and operational flexibility, as stated by CEO Jerry Durso.
Read more →About Altimmune, Inc.
Headquarters910 CLOPPER ROAD, GAITHERSBURG, MD, 20878
Founded1997
BIOPHARMAWATCH ELITE PLUS
Trade the next ALT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime